Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- berotralstat
- Ubrelvy (ubrogepant)
Interactions between your drugs
ubrogepant berotralstat
Applies to: Ubrelvy (ubrogepant), berotralstat
Berotralstat can increase the blood levels of ubrogepant. This may increase side effects such as nausea and sleepiness. The usual recommended dose for migraine is 50 mg in individuals who are receiving treatment with berotralstat. A second dose, if needed, should not be taken for at least 24 hours after the initial dose. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a different dose to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ubrogepant food
Applies to: Ubrelvy (ubrogepant)
Grapefruit and grapefruit juice can increase the blood levels of ubrogepant. This may increase side effects such as nausea and sleepiness. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe an alternative that does not interact, or you may need a different dose to safely use your medication with grapefruit and grapefruit juice. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Haegarda
Haegarda is an injectable protein replacement therapy that prevents swelling and attacks in ...
Takhzyro
Takhzyro (lanadelumab-flyo) is used to prevent hereditary angioedema (HAE) and reduce symptoms ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Orladeyo
Orladeyo (berotralstat) is used to prevent attacks of hereditary angioedema (HAE). Includes ...
Firazyr
Firazyr is used to treat acute attacks of hereditary angioedema (HAE) in adults. It can be ...
Berinert
Berinert is used to treat acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks ...
Cinryze
Cinryze (complement C1 esterase inhibitor) is used to prevent attacks of angioedema in people with ...
Ruconest
Ruconest is used to treat angioedema attacks in adult and adolescent patients with Hereditary ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.